Advancing Abuse Deterrence: Is Delaying Opioid Extraction Enough?
Executive Summary
As the technology improves, so should the minimum expectations to gain an abuse-deterrent labeling claim, FDA advisory committee members say during review of Pfizer's oxycodone/naltrexone extended-release combination Troxyca.
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.
Rare Cancer Development Consortium Moving Toward Target Selection
An upcoming public meeting will include a look at platforms before the first targets are chosen.